CME

Early Treatment of Diabetic Retinopathy and Diabetic Macular Edema: Optimal Use of Anti-VEGF Therapy for Vision Preservation and Restoration

Early Treatment of Diabetic Retinopathy and Diabetic Macular Edema: Optimal Use of Anti-VEGF Therapy for Vision Preservation and Restoration

This activity is supported by an educational grant from Genentech, Inc.

Overview

Author(s)/Faculty: Nancy M. Holekamp, MD; Arshad M. Khanani, MD, MA
Source: Healio - Ophthalmology Education Lab
Type: MultimediaArticles/Items: 4
Release Date: 9/8/2017Expiration Date: 9/8/2018
Credit Type: PhysicianNumber of Credits: 1.25
Cost: FreeProvider: Global UMAParadigm Medical Communications
Diabetic retinopathy (DR) and diabetic macular edema (DME) are 2 of the most common causes of blindness among working-age people throughout the world. Effective management depends heavily on prompt treatment. Many of these patients remain untreated, however; as a result, they often suffer irrevocable vision loss that might have been prevented. Retina specialists and comprehensive ophthalmologists, who play a crucial role in the treatment of DR and DME, will require education to overcome deficits in their knowledge of anti-VEGF therapies for DR and DME, including recent study data elucidating important differences in the safety, efficacy, pharmacology, cost-effectiveness, and delivery of these agents. The proposed interactive video webinar will provide a case-enhanced, expert-led review of anti-VEGF agents (including discussion of a new anti-VEGF delivery mechanism and seminal Protocol S and Protocol T study data), to help retina specialists and comprehensive ophthalmologists provide the early intervention needed to maximize visual outcomes in patients with DME and/or DR.

CME Information

page 1 of 7